Roquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines
The highly complementary profile of five best-in-class medicines consists of:-
- Midkine antibodies with significant in vivo efficacy and toxicology studies;
- Midkine oligonucleotide therapeutics with novel anti-cancer gene editing action;
- Midkine mRNA therapeutics targeting solid tumours;
- STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and
- MK cell therapy with direct and NK-mediated anti-cancer action.
